O'Brien Stephanie Monaghan
Insider CIK 1720907 · APLS Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 27,600 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 7,441 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 8,554 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 11,199 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 5,748 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 14,684 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 121,894 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 17,580 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 27,600 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 3,062 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 5,744 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 7,961 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 3,877 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 3,544 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 25,666 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 5,750 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2026-04-06 | 2026-04-08 | 5,750 | — | $0 | 5,750 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2026-01-01 | 2026-01-05 | 14,684 | — | $0 | 14,684 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-01 | 2026-01-05 | 7,961 | — | $0 | 25,666 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-01-01 | 2025-01-03 | 11,199 | — | $0 | 11,199 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-01 | 2025-01-03 | 6,267 | — | $0 | 17,705 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-01 | 2024-01-02 | 5,748 | $59.86 | $344.1K | 5,748 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-01 | 2024-01-02 | 3,341 | — | $0 | 11,438 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-01 | 2023-01-04 | 7,441 | — | $0 | 7,441 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-01 | 2023-01-04 | 3,867 | — | $0 | 8,097 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-01 | 2022-01-04 | 8,554 | — | $0 | 8,554 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-01 | 2022-01-04 | 4,230 | — | $0 | 4,230 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-01 | 2021-01-04 | 27,600 | — | $0 | 27,600 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2020-01-01 | 2020-01-03 | 27,600 | $30.62 | $845.1K | 27,600 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2019-01-01 | 2019-01-03 | 17,580 | — | $0 | 17,580 | SEC↗ |